FindTrial
Sign In

XL888

DRUG4 trials

Sponsors

Exelixis, H. Lee Moffitt Cancer Center and Research Institute, Emory University

Conditions

CancerColorectal AdenocarcinomaMelanomaMetastatic Pancreatic AdenocarcinomaRecurrent Colorectal CarcinomaRecurrent Pancreatic CarcinomaSkin CancerStage III Colorectal Cancer

Phase 1

Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors
TerminatedNCT00796484
ExelixisCancer
Start: 2008-11-30End: 2010-11-30Updated: 2015-08-21
Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma
CompletedNCT01657591
H. Lee Moffitt Cancer Center and Research InstituteMelanoma
Start: 2012-07-27End: 2021-09-21Updated: 2023-01-19
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
Active, not recruitingNCT02721459
H. Lee Moffitt Cancer Center and Research InstituteMelanoma, Skin Cancer
Start: 2016-09-07End: 2026-11-04Updated: 2026-03-02
Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer
CompletedNCT03095781
Emory UniversityColorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Colorectal Carcinoma +12
Start: 2017-07-07End: 2021-06-10Updated: 2026-05-22

Related Papers

403 Correlative analysis of blood and biopsy samples from a clinical trial of Hsp90 inhibition in combination with pembrolizumab reveals increased intratumoral myeloid cell accumulation after treatment
Regular and Young Investigator Award Abstracts2021-11-01
330 Investigating the clinical safety, efficacy, and immune modulation of combined XL888 and pembrolizumab in metastatic gastrointestinal malignancies
Regular and Young Investigator Award Abstracts2020-11-01
Phase Ib trial of pembrolizumab and XL888 in patients with advanced gastrointestinal malignancies: Results of the dose-escalation phase.
Journal of Clinical Oncology2020-02-019 citations
Phase I study of vemurafenib (VEM) and cobimetinib (COB) with heat shock protein 90 (HSP90) inhibitor XL888 in advanced BRAFV600 mutant melanoma.
Journal of Clinical Oncology2019-05-201 citations
Phase Ib trial of pembrolizumab and XL888 in patients with advanced gastrointestinal malignancies.
Journal of Clinical Oncology2018-02-015 citations
Phase I study of vemurafenib and heat shock protein 90 (HSP90) inhibitor XL888 in metastatic BRAF V600 mutant melanoma.
Journal of Clinical Oncology2016-05-202 citations